<DOC>
	<DOCNO>NCT01059799</DOCNO>
	<brief_summary>This trial conduct Asia Japan . The aim trial compare insulin degludec ( NN1250 ) insulin glargine combine oral antidiabetic drug ( OADs ) subject type 2 diabetes never treat insulin .</brief_summary>
	<brief_title>Comparison NN1250 Versus Insulin Glargine Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>For Japan : minimum age 20 year Type 2 diabetes mellitus ( diagnose clinically ) least 6 month Current treatment monotherapy combination insulin secretagouge ( sulfonylurea glinide ) metformin , without addition alfaglucosidaseinhibitors DPP4 inhibitor unchanged dose least 3 month prior visit 1 . The dose ( ) minimum state : Insulin secretagogue ( sulfonylurea glinide ) : Minimum half daily maximal dose accord local labelling Metformin : alone combination ( include fix combination ) : Maximum tolerate dose alfaglucosidaseinhibitors : Minimum half daily maximal dose maximum tolerated dose DPP4 ( dipeptyl peptidase 4 ) inhibitor : According local labelling HbA1c 7.010.0 % ( inclusive ) central laboratory analysis Body Mass Index ( BMI ) high 35.0 kg/m^2 Use within last 3 month prior Visit 1 : TZDs ( thiazolidinediones ) , exenatide liraglutide Cardiovascular disease , within last 6 month prior visit 1 , define : stroke ; decompensated heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Uncontrolled treated/untreated severe hypertension ( systolic blood pressure least 180 millimetre ( mm ) mercury ( Hg ) and/or diastolic blood pressure least 100 mmHg ) Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure accord local requirement ( Thailand : adequate contraceptive measure : diaphragm , condom ( partner ) , intrauterine device place last three month trial start , sponge , cap spermicide , contraceptive patch , approve hormonal implant ( i.e . Norplant ) , oral contraceptive take without difficulty last three month trial start , post menopausal state sterilisation . ) Cancer medical history cancer ( except basal cell skin cancer squamous cell skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>